This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Mie University. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Yuya Kato: Innovator in Cancer Therapy
Introduction
Yuya Kato is a prominent inventor based in Tsu, Japan. He has made significant contributions to the field of cancer therapy through his innovative research and development of antigen-binding proteins.
Latest Patents
Yuya Kato holds a patent for an antigen-binding protein that recognizes the MAGE-A4-derived peptide. This invention involves CAR-T cells for cancer therapy, which are enhanced with an antibody that recognizes the MAGE-A4-derived-peptide/HLA-A2 complex. The antibody includes the VH amino acid sequence of SEQ ID NO: 36 and the VL amino acid sequence of SEQ ID NO: 38. Additionally, the antibody is preferably provided with the amino acid sequence of SEQ ID NO: 32. Such CAR-T cells can be utilized in CAR infusion therapy, targeting cancer-specific intracellular antigens.
Career Highlights
Yuya Kato is affiliated with Mie University, where he conducts his research and development work. His dedication to advancing cancer treatment through innovative technologies has positioned him as a key figure in the field.
Collaborations
Yuya Kato collaborates with notable colleagues, including Hiroshi Shiku and Yasushi Akahori. Their combined expertise contributes to the advancement of cancer therapies and the development of new treatment methodologies.
Conclusion
Yuya Kato's work in developing antigen-binding proteins for cancer therapy exemplifies the impact of innovation in medical science. His contributions are paving the way for more effective cancer treatments and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile